Epizyme reported $247.6M in Current Assets for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Agios Pharmaceuticals AGIO:US $ 1305.29M 397.28M
Amarin AMRN:US $ 963.03M 32.95M
Amgen AMGN:US $ 24380M 5281M
Avrobio Inc AVRO:US 211.66M 21.86M
Biogen BIIB:US $ 7162.3M 21.4M
Bluebird Bio BLUE:US $ 832.32M 71.2M
Cerulean Pharma CERU:US $ 48.24M 34.18M
Daiichi Sankyo 4568:JP Y 1270181M 36484M
Eisai 4523:JP Y 570717M 8210M
Epizyme EPZM:US $ 247.6M 24.89M
Exelixis EXEL:US $ 1662.03M 68.78M
Gilead Sciences GILD:US $ 14200M 275M
GlaxoSmithKline GSK:LN 18.25B 688M
Glaxosmithkline GSK:US $ 18254M 688M
Karyopharm Therapeutics KPTI:US $ 241.58M 31.92M
Macrogenics MGNX:US $ 334.7M 32.3M
Mirati Therapeutics MRTX:US $ 1171.89M 106.2M
Novartis NOVN:VX 26.25B 2.45B
Novartis NVS:US $ 26253M 2445M
Regeneron Pharmaceuticals REGN:US $ 13775.4M 437.8M
Seattle Genetics SGEN:US $ 3114.61M 16.1M
Spectrum Pharmaceuticals SPPI:US $ 140M 25.71M
Vertex Pharmaceuticals VRTX:US $ 8852.54M 395.03M
Xencor XNCR:US $ 329.63M 151.34M